全文获取类型
收费全文 | 1151篇 |
免费 | 87篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 15篇 |
妇产科学 | 29篇 |
基础医学 | 80篇 |
口腔科学 | 41篇 |
临床医学 | 125篇 |
内科学 | 265篇 |
皮肤病学 | 17篇 |
神经病学 | 61篇 |
特种医学 | 38篇 |
外科学 | 155篇 |
综合类 | 93篇 |
预防医学 | 126篇 |
眼科学 | 23篇 |
药学 | 63篇 |
2篇 | |
中国医学 | 16篇 |
肿瘤学 | 111篇 |
出版年
2024年 | 2篇 |
2023年 | 131篇 |
2022年 | 132篇 |
2021年 | 189篇 |
2020年 | 193篇 |
2019年 | 84篇 |
2018年 | 64篇 |
2017年 | 41篇 |
2016年 | 53篇 |
2015年 | 33篇 |
2014年 | 68篇 |
2013年 | 32篇 |
2012年 | 33篇 |
2011年 | 19篇 |
2010年 | 44篇 |
2009年 | 30篇 |
2008年 | 11篇 |
2007年 | 5篇 |
2006年 | 9篇 |
2005年 | 6篇 |
2004年 | 5篇 |
2003年 | 5篇 |
2002年 | 6篇 |
2001年 | 7篇 |
2000年 | 4篇 |
1999年 | 6篇 |
1998年 | 9篇 |
1997年 | 10篇 |
1996年 | 6篇 |
1995年 | 9篇 |
1994年 | 4篇 |
1993年 | 1篇 |
1992年 | 5篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 3篇 |
排序方式: 共有1265条查询结果,搜索用时 15 毫秒
81.
82.
83.
84.
《Transfusion Clinique et Biologique》2010,17(4):260-264
BackgroundGenerally Rh-negative patients need to be transfused with Rh-negative red blood cells. For pregnant women carrying Rh-positive fetus, the antenatal anti-D detection and Rh immunoglobulin prophylaxis are required worldwide. In East Asia, a RhD variant, termed “Asia type” DEL, was found in approximately 30% of apparent Rh-negative individuals. The antigenic and molecular properties of the DEL were previously defined. Few data discuss whether DEL could be immunized by D antigen clinically although DEL was reported arousing alloimmunization to true Rh-negative patients.Study design and methodsTo determine whether the DEL variant can be immunized to the D antigen, we retrospectively evaluated 104 Rh-negative pregnancies with allo-anti-D antibodies, and we also tracked 199 consecutive apparent Rh-negative pregnant women, with a history of gestations or parturitions but not subject to anti-D gamma-globulin prophylaxis, for evidence of allo-anti-D. The DEL variant was first excluded by ccee phenotypes and then identified through PCR analysis or sequencing.ResultsIn the retrospective study, we expected to find 30 DEL variants, yet none of the anti-D alloimmunized women were DEL-positive. And in the second group, none of 44 DEL-positive women versus 38 of 155 (24.5%) true Rh-negative women (those excluding DEL) formed allo-anti-D.ConclusionThe data indicate that the “Asia type” DEL variant does not appear at risk of alloimmunization to the D antigen. It strongly suggests that the antenatal Rh immune globulin prophylaxis is unnecessary for DEL women. Furthermore, it implicates that the “Asia type” DEL may be deemed Rh-positive safely for clinical transfusion therapy. 相似文献
85.
86.
87.
BackgroundFor human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) with progression on trastuzumab-based therapy, continuing trastuzumab beyond progression and switching to lapatinib combined with chemotherapy are both valid options. We conducted an open-label, randomized phase II trial to compare the efficacy of these strategies.Patients and methodsWomen with HER2-positive MBC previously treated with trastuzumab and taxanes were randomly assigned to receive trastuzumab plus capecitabine (HX) or lapatinib plus capecitabine (LX). The primary endpoint was progression-free survival (PFS) and the secondary endpoints included overall survival (OS) and the objective response rate (ORR). To explore the predictive value of the differential benefit of anti-HER2 drugs, PIK3CA mutations were assessed using circulating tumor DNA.ResultsEighty-six patients (43 in each arm) were enrolled. The median PFS was 6.1 months in the HX arm and 7.1 months in the LX arm (hazard ratio, 0.81; 90% CI, 0.55–1.21; p = 0.39); the median OS was 31.0 months in the HX arm and was not reached in the LX arm (hazard ratio, 0.58; 95% CI, 0.26–1.31; p = 0.18). The ORR was 40% in the HX arm and 41% in the LX arm. PIK3CA mutations were detected in 23% of the 35 analyzed patients, and in patients without PIK3CA mutations, LX yielded relatively longer PFS and OS than HX.ConclusionIn women with HER2-positive MBC previously treated with trastuzumab and taxanes, no significant differences in PFS and OS were observed between patients treated with LX and HX.Trial registration numberUMIN000005219. 相似文献
88.
89.
90.
Xiaoshun He Zhiyong Guo Qiang Zhao Weiqiang Ju Dongping Wang Linwei Wu Lu Yang Fei Ji Yunhua Tang Zhiheng Zhang Shanzhou Huang Linhe Wang Zebin Zhu Kunpeng Liu Yanling Zhu Yifang Gao Wei Xiong Ming Han Bing Liao Maogen Chen Yi Ma Xiaofeng Zhu Wenqi Huang Changjie Cai Xiangdong Guan Xian Chang Li Jiefu Huang 《American journal of transplantation》2018,18(3):737-744
Ischemia and reperfusion injury (IRI) is an inevitable event in conventional organ transplant procedure and is associated with significant mortality and morbidity post‐transplantation. We hypothesize that IRI is avoidable if the blood supply for the organ is not stopped, thus resulting in optimal transplant outcomes. Here we described the first case of a novel procedure called ischemia‐free organ transplantation (IFOT) for patients with end‐stage liver disease. The liver graft with severe macrovesicular steatosis was donated from a 25‐year‐old man. The recipient was a 51‐year‐old man with decompensated liver cirrhosis and hepatocellular carcinoma. The graft was procured, preserved, and implanted under continuous normothermic machine perfusion. The recipient did not suffer post‐reperfusion syndrome or vasoplegia after revascularization of the allograft. The liver function test and histological study revealed minimal hepatocyte, biliary epithelium and vascular endothelium injury during preservation and post‐transplantation. The inflammatory cytokine levels were much lower in IFOT than those in conventional procedure. Key pathways involved in IRI were not activated after allograft revascularization. No rejection, or vascular or biliary complications occurred. The patient was discharged on day 18 post‐transplantation. This marks the first case of IFOT in humans, offering opportunities to optimize transplant outcomes and maximize donor organ utilization. 相似文献